Haoyuan Pharmaceutical and Youweixin join forces to usher in a new era of continuous flow drug synthesis technology
This in-depth cooperation will focus on the innovative application of third-generation wide bandgap semiconductors in the field of optical continuous flow drug synthesis
On July 23, 2025, Shanghai Haoyuan Pharmaceutical Co., Ltd. (stock code: 688131, hereinafter referred to as "Haoyuan Pharmaceutical") and Wuhan Youweixin Technology Co., Ltd. (hereinafter referred to as "Youweixin") officially signed a strategic cooperation agreement in ShanghaiThis in-depth cooperation will focus on the innovative application of third-generation wide bandgap semiconductors in the field of optical continuous flow drug synthesisBy integrating the core advantages of both parties in the fields of chemical synthesis and semiconductor optical technology, we aim to achieve a qualitative leap in momentum transfer, heat transfer, mass transfer, and chemical reaction efficiency in drug production, accelerating the pharmaceutical manufacturing industry's leap from traditional "batch production" to "continuous, intelligent, and low-carbon", and setting a new benchmark for global pharmaceutical research and development and production
Dr. Zheng Baofu, Chairman and General Manager of Haoyuan Pharmaceutical (left)
Professor Chen Changqing, Chairman of Youweixin (right)
As a leading enterprise in the CDMO field, Haoyuan Pharmaceutical has been deeply involved in the research and production of small molecule drugs, ADC drugs, and other fields for many years, and has built an integrated service capability covering "starting materials intermediates active pharmaceutical ingredients formulations". It is in the first tier of the industry in ADC drug research and CDMO field. As of now, the company has served over 990 clients worldwide, supporting more than 50 CMC projects and over 150 load connection sub projects. From 2019 to 2024, its revenue has grown from 409 million yuan to 2.27 billion yuan, with an average annual growth rate of around 40%. It continues to empower the global pharmaceutical research and development process with strong innovation capabilities
Youweixin is the only pioneer enterprise in China that has achieved full spectrum and full industry chain layout of third-generation semiconductor ultraviolet LED, with a complete technical system from epitaxial material growth to light source system integration. Its independently developed deep ultraviolet chip technology achieves full spectrum coverage, with performance indicators such as chip light efficiency reaching a global leading level. It has applied for 325 intellectual property rights and has formed a unique core competitiveness in improving ultraviolet light efficiency, optimizing reliability and system integration, and applying artificial intelligence algorithms. Its products have been widely used in key fields such as new energy vehicles, medical health, and high-end manufacturing
Dr. Zheng Baofu, Chairman of Haoyuan Pharmaceutical, said: "The pharmaceutical industry is currently in a critical period of technological change, and the continuous flow synthesis technology, with its high efficiency and green advantages, is expected to reconstruct the drug production mode. Youweixin's top-notch technical strength in the field of ultraviolet LED chips and system integration perfectly complements Haoyuan Pharmaceutical's profound CDMO industrialization capabilities. This cooperation will accelerate the landing and transformation of manufacturing technology in the pharmaceutical field, help global partners shorten the drug development cycle with advanced manufacturing, bring more efficient treatment solutions to patients, and promote the development of the pharmaceutical industry towards higher quality.
Professor Chen Changqing, Chairman of Youweixin, said: "Youweixin has been deeply involved in the semiconductor ultraviolet LED field for many years and has always been committed to the integration of technological innovation and industrial applications. We believe that the deep collaboration with Haoyuan Pharmaceutical in the field of drug synthesis will effectively break through the technological bottleneck of traditional chemical synthesis and promote the standardized and large-scale application of photocatalytic reactions in the pharmaceutical industry. The collaborative innovation of both parties can not only significantly improve drug production efficiency and reduce production costs, but also provide a new path for the development of green pharmaceutical processes, injecting strong impetus into the sustainable development of the pharmaceutical industry.
The achievement of this strategic cooperation is an important measure for both parties to integrate complementary resources in the fields of chemical synthesis and semiconductor optical technology. By collaborating to explore technological innovations in the third-generation wide bandgap semiconductor for the synthesis of optically continuous flow drugs, both parties will achieve qualitative improvements in momentum transfer, heat transfer, mass transfer, and chemical reaction efficiency, promoting the leapfrog upgrade and transformation of pharmaceutical manufacturing from "batch production" to "continuous, intelligent, and low-carbon". This cooperation not only opens a new chapter in pharmaceutical manufacturing technology innovation, but also sets a new benchmark for technological innovation and green development in the pharmaceutical manufacturing industry, and will contribute an important force to the progress of the global pharmaceutical industry
About Haoyuan Pharmaceutical
Shanghai Haoyuan Pharmaceutical Co., Ltd. (stock code: 688131) was established in 2006, focusing on providing integrated services from drug discovery to commercial production for the global pharmaceutical industry. The company is at the forefront of ADC drug research and CDMO in the industry, and has built an integrated service capability covering "starting materials intermediates active pharmaceutical ingredients formulations". It has served over 990 customers worldwide, supporting more than 50 CMC projects and over 150 load connection sub projects. From 2019 to 2024, the company's revenue increased from 409 million yuan to 2.27 billion yuan, with an average annual growth rate of around 40%, continuously empowering global pharmaceutical research and development with strong innovation capabilities
About Youweixin
Wuhan Youweixin Technology Co., Ltd. is the only chip enterprise in China that covers the full spectrum and entire industry chain of semiconductor ultraviolet LED. It has a complete technical system from epitaxial material growth to light source system integration. The company has applied for a total of 325 intellectual property rights, forming core competitiveness in areas such as improving UV efficiency and optimizing reliability. The independently developed UV LED products have global leading performance and have been widely used in fields such as new energy vehicles, medical health, and high-end manufacturing, providing strong support for technological upgrading and innovative development in various industries
